EN DE
Watch Shanghai Universal Biotech Co.Ltd. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Shanghai Universal Biotech Co.Ltd. (301166) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Shanghai Universal Biotech Co.Ltd. stock ¥23.30, price ¥24.36, that is 4.4% below the price, quality 50 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100005709

SU Shanghai Universal Biotech Co.Ltd. logo Thin data Nov 16, 2026

Shanghai Universal Biotech Co.Ltd.

301166 · SHE

Solid company, but the stock is already about fairly priced and price moving sideways: meets 1 of 3 rules.

Follow free in the weekly email
Ranks above peers (9/10) 
Fair value ¥23.30 · Fairly valued 
Quality 50/100 
Price moving sideways (no uptrend) 
2.5% dividend yield · Watch coverage
Profit last quarter 46% below a year ago. 
Weak Growth (revenue 3y −3.2 %/yr in CNY) 
Loss-making · -1.9% net margin (TTM) 
Negative free cash flow 
Narrow moat 15/100 · thin data
Thin data 
Estimate
Watch Shanghai Universal Biotech Co.Ltd. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥122.84 ¥22.92 Fair Value ¥23.30 Dec 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

59‑month range ¥22.92 – ¥122.84 · fair‑value band ¥17.47 – ¥29.12 · the ¥24.36 price screens above the ¥23.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Shanghai Universal Biotech Co.Ltd. in your weekly email

Every Wednesday you see whether Shanghai Universal Biotech Co.Ltd. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shanghai Universal Biotech Co.,Ltd. distributes and supplies antibodies and protein products. The company offers antibodies, recombinant proteins, detection kits, antigens, and other products, as well as immunology reagents, molecular biology reagents, cell biology reagents and biochemical reagents.

Show moreShow less

It also provides technical services, technology promotion, technology information exchange, scientific and technology training, technology consulting, technology incubation and other services, as well as experimental services and software solutions. The company also sells products online.

It serves colleges and universities, research institutes, hospitals, and biomedical companies. The company was founded in 2004 and is based in Shanghai, China.

Stock analysis

Shanghai Universal Biotech Co.Ltd. (301166) currently trades at ¥24.36, while our estimate is ¥23.30, so the stock looks roughly fairly valued today (gap 4.6%).

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥17.47 (bear) to ¥29.12 (bull), the price of ¥24.36 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Shanghai Universal Biotech Co.Ltd. reported revenue of 1.1B CNY in FY2025 versus 1.1B CNY in FY2021, a compound −0.6%/yr. Reported net income was −22.9M CNY in FY2025.

Key figures

Market cap 2.1B CNY (≈ $315M) Small · P/S ratio 2.14 · EPS (TTM) ¥-0.25 · Dividend yield 2.5% · Net margin −1.9% · Return on equity −1.1% · Return on assets (EBIT) 1.6% (5-year average) · Operating margin −4.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −4%, 301166 screens richer than that median.

Fair Value

Bear ¥17.47 Fair Value ¥23.30 Bull ¥29.12
Price ¥24.36 · Downside -4.4%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 15
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 87
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 17/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.3% (2020) → −3.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 301166, get fair value alerts →

Compare Shanghai Universal Biotech Co.Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 854 stocks

Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −4.4% · Top 25%
Profitability
Return on assets −1.0% · Top 25%
Net margin (12 months) −1.9% · Above median
Operating margin (12 months) −4.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 7.2% · Above median
Dividend yield (12 months) 2.5% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.05× · Cheapest 25%
P/S (12 months) 1.83× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)27 · sector 0
FUTURE (revenue growth)36 · sector 32
PAST (return on equity)0 · sector 0
HEALTH (low debt)–
DIVIDEND (yield)49 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $920.69 $1,275.02 +38% vs 301166
Vertex Pharmaceuticals Incorporated VRTX $515.02 $566.52 +10% vs 301166
Samsung Biologics Co 207940 ₩1,355,000 ₩1,490,500 +10% vs 301166
argenx SE ARGX $925.70 $908.40 −2% vs 301166
CSL Limited CSL A$197.29 A$188.80 −4% vs 301166
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs 301166
Moderna, Inc MRNA $195.00 $119.97 −38% vs 301166
Revolution Medicines, Inc RVMD $161.20 $83.14 −48% vs 301166
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs 301166
Royalty Pharma plc RPRX $68.45 $19.01 −72% vs 301166

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shanghai Universal Biotech Co.Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shanghai Universal Biotech Co.Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/301166

Frequently asked questions

Is Shanghai Universal Biotech Co.Ltd. (301166) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ¥23.30 versus a price of ¥24.36, about 4% lower (fairly valued).
What is the fair value of 301166?
Our estimate for Shanghai Universal Biotech Co.Ltd. is ¥23.30 (as of Nov 16, 2026), built from audited fundamentals. The current price: ¥24.36.
What is the quality score of 301166?
Shanghai Universal Biotech Co.Ltd. has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Universal Biotech Co.Ltd. (301166)?
We do not set a price target; the yardstick is our estimate of ¥23.30 (as of Nov 16, 2026). Cautious scenario ¥17.47, optimistic scenario ¥29.12. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Shanghai Universal Biotech Co.Ltd. stock forecast for 2026?
Our estimate puts fair value at ¥23.30, about 4% lower versus a price of ¥24.36 (fairly valued). Cautious scenario ¥17.47, optimistic scenario ¥29.12. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Universal Biotech Co.Ltd. (301166)?
Shanghai Universal Biotech Co.Ltd. reported trailing-twelve-month revenue of about 1.1B CNY (latest available figure, as of Nov 16, 2026).
Does Shanghai Universal Biotech Co.Ltd. pay a dividend?
Shanghai Universal Biotech Co.Ltd. currently shows a dividend yield of 2.46% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Shanghai Universal Biotech Co.Ltd. (301166) and when is the ex-dividend date?
Shanghai Universal Biotech Co.Ltd. pays a dividend of ¥0.6 per share a year, a dividend yield of 2.5%. The last ex-dividend date was Jun 1, 2026. A dividend has been paid every year since at least 2022. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Shanghai Universal Biotech Co.Ltd. (301166)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Universal Biotech Co.Ltd. it is ¥23.30 per share (as of Nov 16, 2026), against a price of ¥24.36.
Is Shanghai Universal Biotech Co.Ltd. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 301166 trades above its calculated fair value: price ¥24.36, fair value ¥23.30, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301166?
No. The price is what the market pays today (¥24.36); the fair value is what the company's own numbers justify (¥23.30). For Shanghai Universal Biotech Co.Ltd. the two are ¥1.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Universal Biotech Co.Ltd. worth?
The market values Shanghai Universal Biotech Co.Ltd. at about 2.1B CNY (market capitalisation, as of Nov 16, 2026). Per share that is ¥24.36; our models calculate a fair value of ¥23.30 per share.
What do the bullish and bearish scenarios say about 301166?
Our models span a range for Shanghai Universal Biotech Co.Ltd.: cautious scenario ¥17.47, base ¥23.30, optimistic ¥29.12 per share (as of Nov 16, 2026, price ¥24.36). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shanghai Universal Biotech Co.Ltd. (301166)?
Balance-sheet figures for Shanghai Universal Biotech Co.Ltd. (as of Nov 16, 2026): return on equity −1.1%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 301166 from its 52-week high?
Shanghai Universal Biotech Co.Ltd. trades at ¥24.36, about 33% below its 52-week high of ¥36.42 and 1% above the low of ¥24.09 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of ¥23.30 is for.
Which stocks are comparable to Shanghai Universal Biotech Co.Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Universal Biotech Co.Ltd. stock attractive at the current price?
The data as of Nov 16, 2026: price ¥24.36, calculated fair value ¥23.30 (−4%), Quality Score 50/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Shanghai Universal Biotech Co.Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Universal Biotech Co.Ltd. (301166)?
The closing price on Nov 20, 2026 was ¥24.36. Our estimate is ¥23.30, about 4% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Universal Biotech Co.Ltd. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Shanghai Universal Biotech Co.Ltd.

How large is the market capitalisation of Shanghai Universal Biotech Co.Ltd. (301166)?
The market capitalisation of Shanghai Universal Biotech Co.Ltd. is 2.1B CNY (≈ $315M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Universal Biotech Co.Ltd. (301166)?
The price-to-sales ratio of Shanghai Universal Biotech Co.Ltd. is 2.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Universal Biotech Co.Ltd. (301166)?
Earnings per share at Shanghai Universal Biotech Co.Ltd. are ¥-0.25. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Universal Biotech Co.Ltd. (301166)?
The dividend yield of Shanghai Universal Biotech Co.Ltd. is 2.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Universal Biotech Co.Ltd. (301166)?
The net margin of Shanghai Universal Biotech Co.Ltd. is −1.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Universal Biotech Co.Ltd. (301166)?
The return on equity (ROE) of Shanghai Universal Biotech Co.Ltd. is −1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Universal Biotech Co.Ltd. (301166)?
On an EBIT basis the return on assets of Shanghai Universal Biotech Co.Ltd. is 1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Universal Biotech Co.Ltd. (301166)?
The operating margin of Shanghai Universal Biotech Co.Ltd. is −4.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Universal Biotech Co.Ltd. (301166)?
Revenue at Shanghai Universal Biotech Co.Ltd. is growing 7.2% in the last quarter versus the same quarter a year earlier (3y avg −3.2%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How fast are earnings growing at Shanghai Universal Biotech Co.Ltd. (301166)?
Earnings per share at Shanghai Universal Biotech Co.Ltd. are down 45.6% in the last quarter versus the same quarter a year earlier. How much earnings per share grew in the last quarter versus the same quarter a year earlier.
How much free cash flow does Shanghai Universal Biotech Co.Ltd. (301166) generate?
The free cash flow of Shanghai Universal Biotech Co.Ltd. is −43.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Shanghai Universal Biotech Co.Ltd. in the live analysis

One click puts Shanghai Universal Biotech Co.Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.